Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$1.80 USD
-0.01 (-0.28%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $1.80 +0.01 (0.28%) 7:28 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Tilray Brands, Inc. [TLRY]
Reports for Purchase
Showing records 101 - 120 ( 219 total )
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Canadian LP Update: Strong Liquidity on U.S. Reform, Elevated LP Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Cannabis Industry 3Q & Election Recap: Bifurcation in Markets and Returns
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Muted 3Q Results, Optimized Cost Structure Leads to Operational Leverage
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
3Q20 Preview, Looking for Global and 2.0 Growth
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Key Highlights to Track for U.S. Cannabis on Election Night
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
2Q20 Results Weak Sales in Canada, Show Operational Improvements
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Canadian LP Cannabis Outlook and 2Q20 Preview
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S